Edgewise Therapeutics Ownership | Who Owns Edgewise Therapeutics?


OverviewForecastRevenueFinancialsChart

Edgewise Therapeutics Ownership Summary


Edgewise Therapeutics is owned by 107.98% institutional investors, 0.46% insiders. Orbimed advisors is the largest institutional shareholder, holding 17.15% of EWTX shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.67% of its assets in Edgewise Therapeutics shares.

EWTX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockEdgewise Therapeutics107.98%0.46%-8.45%
SectorHealthcare Stocks 49.73%8.84%41.43%
IndustryBiotech Stocks 47.04%8.74%44.21%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Orbimed advisors15.02M17.15%$270.54M
Ra capital management8.91M10.17%$160.45M
Novo6.34M7.25%$114.26M
Blackrock6.02M6.87%$108.34M
Baker bros. advisors lp5.84M6.67%$105.18M
Fmr4.78M5.46%$86.10M
Vanguard group4.51M5.15%$81.19M
Frazier life sciences management3.73M4.26%$67.20M
Cormorant asset management, lp3.01M3.43%$54.15M
Deerfield management company, l.p. (series c)2.87M3.28%$51.77M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
New leaf venture partners1.55M34.03%$27.98M
Novo6.34M5.73%$114.26M
Orbimed advisors15.02M5.38%$270.54M
Tcg crossover management2.27M4.27%$40.93M
Frazier life sciences management3.73M3.14%$67.20M
Cormorant asset management, lp3.01M3.13%$54.15M
Opaleye management580.00K2.39%$10.45M
Ra capital management8.91M2.12%$160.45M
Vr adviser1.82M2.09%$32.75M
Bioimpact capital740.66K2.07%$13.34M

Top Buyers

HolderShares% AssetsChange
Novo6.34M5.73%6.34M
Bellevue group1.43M0.42%1.43M
Blackrock6.02M0.00%848.71K
Janus henderson group2.61M0.03%801.99K
Millennium management1.15M0.01%613.25K

Top Sellers

HolderShares% AssetsChange
Viking global investors lp1.48M0.10%-1.86M
Fmr4.78M0.01%-1.59M
Balyasny asset management---528.59K
Perceptive advisors1.86M0.79%-463.23K
Exoduspoint capital management, lp---268.14K

New Positions

HolderShares% AssetsChangeValue
Bellevue group1.43M0.42%1.43M$25.74M
Sofinnova investments475.69K0.45%475.69K$8.57M
Stempoint capital lp271.06K1.43%271.06K$4.88M
Polar asset management partners187.50K0.07%187.50K$3.38M
Adage capital partners gp49.60K0.00%49.60K$893.24K

Sold Out

HolderChange
Pnc financial services group-4.00
Creekmur asset management-8.00
Nelson, van denburg & campbell wealth management group-8.00
Allworth financial lp-45.00
Comerica bank-57.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202418833.33%101,300,175-0.31%1070.80%11223.08%4348.28%
Jun 30, 20241419.30%101,619,83810.90%1161.06%911.11%293.57%
Mar 31, 20241299.32%91,633,56715.05%1040.67%9011.11%2840.00%
Dec 31, 202311837.21%79,648,50316.42%1241.08%8165.31%2017.65%
Sep 30, 202386-10.42%68,414,835-1.53%1070.90%49-3.92%17-26.09%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv2.52M2.67%-12.28K
iShares Russell 2000 ETF1.87M1.97%-4.20K
BB Biotech AG Ord1.43M1.52%-
Fidelity Small Cap Growth983.35K1.05%-284.60K
Vanguard Institutional Extnd Mkt Idx Tr872.07K0.92%-6.14K
American Century U.S. Small Cap Growth805.79K0.86%122.16K
American Century Small Cap Growth Inv805.79K0.86%122.16K
Fidelity Small Cap Index743.23K0.79%-19.20K
Artisan International Small-Mid Investor648.81K0.69%648.81K
Artisan Non-U.S. Small-Mid Growth Comp648.81K0.69%648.81K

Recent Insider Transactions


DateNameRoleActivityValue
Sep 20, 2024Russell Alan J Chief Scientific OfficerSell$24.05K
Sep 20, 2024Russell Alan J Chief Scientific OfficerSell$2.10M
Sep 23, 2024MOORE JOHN R General CounselSell$578.06K
Sep 20, 2024MOORE JOHN R General CounselSell$1.42M
Sep 20, 2024Donovan Joanne M. CMOSell$202.60K

Insider Transactions Trends


DateBuySell
2024 Q3-10
2024 Q2-6
2024 Q127
2023 Q412
2023 Q3--

EWTX Ownership FAQ


Who Owns Edgewise Therapeutics?

Edgewise Therapeutics shareholders are primarily institutional investors at 107.98%, followed by 0.46% insiders and -8.44% retail investors. The average institutional ownership in Edgewise Therapeutics's industry, Biotech Stocks , is 47.04%, which Edgewise Therapeutics exceeds.

Who owns the most shares of Edgewise Therapeutics?

Edgewise Therapeutics’s largest shareholders are Orbimed advisors (15.02M shares, 17.15%), Ra capital management (8.91M shares, 10.17%), and Novo (6.34M shares, 7.25%). Together, they hold 34.57% of Edgewise Therapeutics’s total shares outstanding.

Does Blackrock own Edgewise Therapeutics?

Yes, BlackRock owns 6.87% of Edgewise Therapeutics, totaling 6.02M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 108.34M$. In the last quarter, BlackRock increased its holdings by 848.7K shares, a 16.43% change.

Who is Edgewise Therapeutics’s biggest shareholder by percentage of total assets invested?

New leaf venture partners is Edgewise Therapeutics’s biggest shareholder by percentage of total assets invested, with 34.03% of its assets in 1.55M Edgewise Therapeutics shares, valued at 27.98M$.

Who is the top mutual fund holder of Edgewise Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Edgewise Therapeutics shares, with 2.67% of its total shares outstanding invested in 2.52M Edgewise Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools